Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1810 results
June 2017
-
Media Release
Novartis landmark study of Tafinlar® + Mekinist® demonstrates durable survival benefit at five years in patients with BRAF mutation-positive metastatic melanoma
Study is longest follow-up to date of a BRAF and MEK inhibitor combination therapy in patients with BRAF V600-mutant metastatic melanoma[1] Study shows stable overall survival and progression-free… -
Story Discovery
Innovating on a trusted class of antibiotics to attack superbugs
A new compound aims to attack dangerous antibiotic-resistant bacteria.
-
Story Discovery
Women in Science: Cathryn Clary
Our Global Head of Patient Affairs and Policy shares why it’s critical to engage patients throughout the drug development process.
-
Media Release
Novartis presents updated data that reinforce the efficacy and safety of Kisqali® (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer
At a subsequent analysis of the MONALEESA-2 trial, after nearly one year of additional follow-up, Kisqali plus letrozole demonstrated median progression-free survival (PFS) of 25.3 months compared… -
Story From Our Labs
Minion challenges assumptions about the genome
A diminutive protein prompts a closer look at DNA dark matter.
May 2017
-
Media Release
Progress reported in global fight against diarrheal disease cryptosporidiosis
Novartis, the University of Georgia, Washington State University and collaborators advance therapeutic research for cryptosporidiosis Research collaboration with novel drug discovery process… -
Media Release
Sandoz proposed biosimilars adalimumab and infliximab accepted for regulatory review by the European Medicines Agency
Sandoz is seeking approval for their proposed biosimilars adalimumab and infliximab for use in all indications of their respective reference medicines, Humira®* and Remicade®** Comprehensive data… -
Media Release
At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018
Building depth across key therapeutic areas with 12 potential blockbusters in late stage development and 40 potential filings in US and EU between 2017-2020 Focused and taking steps to become… -
Media Release
Novartis next generation CAR-T cell therapy CTL119 combined with ibrutinib shows high rate of responses in CLL patients
Eight of nine evaluable patients tested had no signs of CLL in their bone marrow at three months.CTL119 is a humanized CD19-directed CAR-T cell therapy being developed in collaboration with the… -
Media Release
Novartis receives FDA approval for expanded use of Zykadia® in first-line ALK-positive metastatic non-small cell lung cancer (NSCLC)
In ALK-positive metastatic NSCLC patients, Zykadia median progression-free survival (PFS) was 16.6 months, compared to 8.1 months with chemotherapy[1] The overall intracranial response rate… -
Story Discovery
Going global to meet local needs in China
Marc Pelletier traveled from Cambridge, MA to Shanghai, China, to launch new lines of research for the treatment of cancers that are common in China.
-
Story Patient Perspectives
Choosing the right care
Melanoma survivor T.J. Sharpe shares why patients should know their treatment options.